The Scottish Medicines Consortium (SMC) has rejected Daiichi Sankyo’s new cholesterol-lowering drug Nilemdo for use by NHS Scotland, saying the evidence backing the drug isn’t strong enough.

The CHMP also backed Nilemdo (bempedoic acid) and Nustendi (bempedoic acid/ezetimibe) for the treatment of primary hypercholesterolaemia and mixed dyslipidaemia, originally developed by Esperion ...

Laila Maidan is a Tech and Investing reporter at MarketWatch. She covers the rapid developments in the sector along with actionable investment recommendations and deep dives into valuations.